These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 19264130)

  • 1. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
    Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I
    Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
    Vulih-Shultzman I; Pinhasov A; Mandel S; Grigoriadis N; Touloumi O; Pittel Z; Gozes I
    J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAP has no effect on spatial memory after short-term treatment in advanced stage Alzheimer's disease mouse model.
    Van Dijck A; Van Dam D; De Deyn PP
    Peptides; 2009 Dec; 30(12):2480-2. PubMed ID: 19664667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
    Gozes I; Iram T; Maryanovsky E; Arviv C; Rozenberg L; Schirer Y; Giladi E; Furman-Assaf S
    J Alzheimers Dis; 2014; 40 Suppl 1():S23-36. PubMed ID: 24503616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
    Nakashima H; Ishihara T; Suguimoto P; Yokota O; Oshima E; Kugo A; Terada S; Hamamura T; Trojanowski JQ; Lee VM; Kuroda S
    Acta Neuropathol; 2005 Dec; 110(6):547-56. PubMed ID: 16228182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.
    Jouroukhin Y; Ostritsky R; Gozes I
    J Mol Neurosci; 2012 Nov; 48(3):597-602. PubMed ID: 22956189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
    Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
    Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze.
    Alcalay RN; Giladi E; Pick CG; Gozes I
    Neurosci Lett; 2004 May; 361(1-3):128-31. PubMed ID: 15135910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3R tau expression modifies behavior in transgenic mice.
    Shiryaev N; Jouroukhin Y; Gozes I
    J Neurosci Res; 2010 Sep; 88(12):2727-35. PubMed ID: 20544828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
    Sydow A; Mandelkow EM
    Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of murine tau gene increases tau aggregation in a human mutant tau transgenic mouse model.
    Ando K; Leroy K; Heraud C; Kabova A; Yilmaz Z; Authelet M; Suain V; De Decker R; Brion JP
    Biochem Soc Trans; 2010 Aug; 38(4):1001-5. PubMed ID: 20658993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regional distribution of phosphorylated tau and synapse loss in the nucleus accumbens in tauopathy model mice.
    Kambe T; Motoi Y; Inoue R; Kojima N; Tada N; Kimura T; Sahara N; Yamashita S; Mizoroki T; Takashima A; Shimada K; Ishiguro K; Mizuma H; Onoe H; Mizuno Y; Hattori N
    Neurobiol Dis; 2011 Jun; 42(3):404-14. PubMed ID: 21324362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.
    Boimel M; Grigoriadis N; Lourbopoulos A; Touloumi O; Rosenmann D; Abramsky O; Rosenmann H
    J Neuropathol Exp Neurol; 2009 Mar; 68(3):314-25. PubMed ID: 19225406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
    Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
    Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model.
    Corcoran NM; Martin D; Hutter-Paier B; Windisch M; Nguyen T; Nheu L; Sundstrom LE; Costello AJ; Hovens CM
    J Clin Neurosci; 2010 Aug; 17(8):1025-33. PubMed ID: 20537899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau.
    Tatebayashi Y; Miyasaka T; Chui DH; Akagi T; Mishima K; Iwasaki K; Fujiwara M; Tanemura K; Murayama M; Ishiguro K; Planel E; Sato S; Hashikawa T; Takashima A
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13896-901. PubMed ID: 12368474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
    Shiryaev N; Pikman R; Giladi E; Gozes I
    Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy.
    Yue M; Hanna A; Wilson J; Roder H; Janus C
    Neurobiol Aging; 2011 Apr; 32(4):590-603. PubMed ID: 19427061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.